The_DT Candida_NP dubliniensis_NN CdCDR1_NP Gene_NP Is_VBZ Not_RB Essential_JJ for_IN Fluconazole_NP Resistance_NP The_DT present_JJ study_NN investigated_VBD the_DT role_NN of_IN the_DT Candida_NP dubliniensis_NN CdCDR1_NP and_CC CdCDR2_NP genes_NNS in_IN the_DT development_NN of_IN fluconazole_NN resistance_NN ._SENT The_DT C._NP dubliniensis_NN CdCDR1_NP gene_NN was_VBD 92_CD %_NN identical_JJ at_IN the_DT nucleotide_NN sequence_NN level_NN to_TO the_DT corresponding_JJ C._NP albicans_NNS gene_NN ._SENT However_RB ,_, 58_CD %_NN (_( 14_CD of_IN 24_CD )_) of_IN C._NP dubliniensis_NN genotype_NN 1_CD isolates_NNS tested_VBN harbored_VBD a_DT nonsense_JJ mutation_NN in_IN the_DT CdCDR1_JJ open_JJ reading_NN frame_NN that_WDT converted_VBD codon_NN 756_CD (_( TAT_NP )_) to_TO a_DT TAG_NP translational_JJ stop_NN codon_NN ._SENT Analysis_NN of_IN five_CD of_IN these_DT C._NP dubliniensis_NN isolates_VBZ by_IN Western_JJ immunoblotting_NN showed_VBD that_IN they_PP expressed_VBD a_DT truncated_JJ 85-kDa_JJ CdCdr1p_NN compared_VBN to_TO the_DT full-length_JJ 170-kDa_NP CdCdr1p_NP ._SENT Expression_NN of_IN CdCDR1_JJ alleles_NNS from_IN six_CD C._NP dubliniensis_NN isolates_VBZ in_IN a_DT pdr5_JJ Saccharomyces_NP cerevisiae_NNS strain_NN revealed_VBD that_IN CdCDR1_JJ alleles_NNS from_IN three_CD isolates_NNS that_WDT encoded_VBD truncated_JJ proteins_NNS were_VBD unable_JJ to_TO confer_VB resistance_NN to_TO drugs_NNS and_CC antifungals_NNS ._SENT However_RB ,_, reassignment_NN of_IN the_DT TAG_NP sequence_NN at_IN codon_NN 756_CD to_TO TAT_NP (_( encoding_VBG tyrosine_NN )_) in_IN an_DT allele_NN from_IN strain_NN CD36_NP conferred_VBD the_DT ability_NN to_TO mediate_VB resistance_NN to_TO multiple_JJ drugs_NNS ._SENT Fluconazole-resistant_JJ isolates_NNS of_IN C._NP dubliniensis_NN harboring_VBG functional_JJ alleles_NNS of_IN CdCDR1_NP were_VBD found_VBN to_TO exhibit_VB two-_NN to_TO ninefold-higher_NN levels_NNS of_IN CdCDR1_JJ mRNA_NN than_IN did_VBD matched_VBN fluconazole-susceptible_JJ isolates_NNS ._SENT By_IN comparison_NN ,_, levels_NNS of_IN CdMDR1_JJ expression_NN ranged_VBN from_IN approximately_RB 50-_CD to_TO 100-fold_NN greater_JJR in_IN resistant_JJ isolates_NNS ._SENT Fluconazole_NP resistance_NN was_VBD also_RB identified_VBN in_IN isolates_NNS harboring_VBG nonfunctional_JJ CdCDR1_JJ alleles_NNS ,_, but_CC resistance_NN in_IN these_DT isolates_NNS was_VBD only_RB associated_VBN with_IN increased_VBN CdMDR1_JJ expression_NN ._SENT Targeted_JJ disruption_NN of_IN two_CD functional_JJ alleles_NNS of_IN CdCDR1_NP in_IN a_DT fluconazole-resistant_JJ derivative_NN of_IN C._NP dubliniensis_NN that_WDT overexpressed_VBD both_DT CdCDR1_NP and_CC CdMDR1_NP revealed_VBD that_IN although_IN CdCDR1_NP was_VBD important_JJ for_IN mediating_VBG reduced_VBN susceptibility_NN to_TO itraconazole_NN and_CC ketoconazole_NN ,_, there_EX was_VBD no_DT affect_NN on_IN fluconazole_NN susceptibility_NN in_IN the_DT double_JJ mutant_NN ._SENT Evidence_NN presented_VBD in_IN this_DT study_NN reveals_VBZ that_IN CdCDR1_NP is_VBZ not_RB essential_JJ for_IN the_DT development_NN of_IN fluconazole_NN resistance_NN in_IN C._NP dubliniensis_NN ._SENT Resistance_NN to_TO azole_NN antifungal_NN drugs_NNS in_IN Candida_NP species_NN is_VBZ now_RB recognized_VBN as_IN a_DT major_JJ clinical_JJ problem_NN ._SENT Several_JJ studies_NNS have_VBP shown_VBN that_IN a_DT significant_JJ proportion_NN of_IN oral_JJ Candida_NP albicans_NNS isolates_NNS recovered_VBD from_IN human_JJ immunodeficiency_NN virus_NN (HIV)-infected_JJ patients_NNS are_VBP resistant_JJ to_TO the_DT azole_NN antifungal_JJ drug_NN fluconazole_NN and_CC that_IN some_DT non-C_NN ._SENT albicans_NP Candida_NP species_NNS ,_, such_JJ as_IN Candida_NP krusei_NP ,_, are_VBP inherently_RB resistant_JJ to_TO this_DT agent_NN ._SENT Fluconazole_NN resistance_NN has_VBZ also_RB been_VBN described_VBN in_IN Candida_NP dubliniensis_NN ,_, a_DT species_NN that_WDT was_VBD first_RB described_VBN in_IN 1995_CD ._SENT C._NP dubliniensis_NN is_VBZ a_DT significant_JJ cause_NN of_IN oral_JJ disease_NN in_IN the_DT HIV-infected_JJ patient_NN population_NN ,_, who_WP routinely_RB receive_VBP fluconazole_NN therapy_NN for_IN the_DT suppression_NN of_IN oral_JJ candidiasis_NN ._SENT Recently_RB ,_, several_JJ studies_NNS have_VBP reported_VBN the_DT recovery_NN of_IN C._NP dubliniensis_NN from_IN the_DT bloodstream_NN ,_, although_IN the_DT true_JJ incidence_NN of_IN systemic_JJ infection_NN caused_VBN by_IN this_DT organism_NN has_VBZ yet_RB to_TO be_VB determined_VBN ._SENT We_PP and_CC others_NNS have_VBP previously_RB reported_VBN the_DT recovery_NN of_IN C._NP dubliniensis_NN isolates_VBZ with_IN reduced_VBN susceptibility_NN to_TO fluconazole_NN from_IN the_DT oral_JJ cavities_NNS of_IN HIV-infected_JJ patients_NNS ._SENT In_IN addition_NN ,_, we_PP have_VBP shown_VBN that_IN fluconazole-susceptible_JJ C._NP dubliniensis_NN clinical_JJ isolates_NNS can_MD readily_RB develop_VB fluconazole_NN resistance_NN when_WRB exposed_VBN to_TO this_DT agent_NN in_IN vitro_NN ._SENT Molecular_JJ analysis_NN of_IN fluconazole-resistant_JJ C._NP dubliniensis_NN isolates_NNS and_CC in_IN vitro-generated_JJ fluconazole-resistant_JJ derivatives_NNS has_VBZ shown_VBN that_IN in_IN each_DT case_NN ,_, the_DT fluconazole_NN resistance_NN phenotype_NN is_VBZ associated_VBN with_IN increased_VBN expression_NN of_IN the_DT CdMDR1_JJ gene_NN encoding_VBG the_DT multidrug_NN transporter_NN CdMdr1p_NP ._SENT Wirsching_NP et_FW al._FW demonstrated_VBD that_IN targeted_JJ deletion_NN of_IN both_DT copies_NNS of_IN CdMDR1_NP in_IN a_DT C._NP dubliniensis_NN clinical_JJ isolate_NN with_IN reduced_VBN susceptibility_NN to_TO fluconazole_NN was_VBD sufficient_JJ to_TO render_VB the_DT null_JJ mutant_NN susceptible_JJ to_TO fluconazole_NN ._SENT A_DT second_JJ multidrug_NN transporter-encoding_NN gene_NN ,_, termed_VBD CdCDR1_NP ,_, has_VBZ also_RB been_VBN identified_VBN in_IN C._NP dubliniensis_NN ,_, and_CC it_PP is_VBZ homologous_JJ to_TO the_DT C._NP albicans_NP ABC_NP transporter-encoding_NN gene_NN CDR1_NP ._SENT Almost_RB all_DT isolates_NNS of_IN C._NP albicans_NNS (_( 83_CD %_NN )_) with_IN reduced_VBN susceptibility_NN to_TO azoles_NNS analyzed_VBN to_TO date_NN exhibit_NN increased_VBD expression_NN of_IN CDR1_NP ._SENT However_RB ,_, the_DT role_NN of_IN the_DT homologous_JJ CdCDR1_JJ gene_NN in_IN C._NP dubliniensis_NN in_IN determining_VBG susceptibility_NN to_TO fluconazole_NN is_VBZ less_RBR clear_JJ ._SENT Although_IN increased_VBN expression_NN of_IN CdMDR1_NP has_VBZ been_VBN observed_VBN in_IN all_DT fluconazole-resistant_JJ C._NP dubliniensis_NN isolates_NNS and_CC derivatives_NNS analyzed_VBD to_TO date_NN ,_, increased_VBD CdCDR1_JJ gene_NN expression_NN has_VBZ only_RB been_VBN reported_VBN in_IN approximately_RB 50_CD %_NN of_IN fluconazole-resistant_JJ C._NP dubliniensis_NN isolates_NNS and_CC derivatives_NNS ._SENT For_IN these_DT reasons_NNS ,_, the_DT objectives_NNS of_IN the_DT present_JJ study_NN were_VBD to_TO functionally_RB characterize_VB the_DT C._NP dubliniensis_NN CdCDR1_NP gene_NN and_CC to_TO examine_VB its_PP$ role_NN in_IN determining_VBG azole_NN susceptibility_NN in_IN C._NP dubliniensis_NN ._SENT Candida_NP strains_NNS and_CC culture_NN conditions_NNS ._SENT |_SYM Forty_NP clinical_JJ isolates_NNS of_IN C._NP dubliniensis_NN from_IN diverse_JJ geographic_JJ locations_NNS were_VBD included_VBN in_IN this_DT study_NN ._SENT Isolates_NNS of_IN C._NP dubliniensis_NN were_VBD routinely_RB cultured_VBN on_IN potato_NN dextrose_NN agar_NN (_( Oxoid_JJ )_) medium_NN ,_, pH_NN 5.6_CD ,_, at_IN 37C_JJ ._SENT For_IN liquid_JJ culture_NN ,_, cells_NNS were_VBD grown_VBN in_IN yeast_NN extract-peptone-dextrose_NN (_( YEPD_NP )_) broth_NN ,_, also_RB at_IN 37C_JJ ._SENT Transformants_NNS of_IN C._NP dubliniensis_NP and_CC Saccharomyces_NP cerevisiae_NNS were_VBD selected_VBN and_CC maintained_VBN on_IN minimal_JJ agar_NN medium_NN (_( 6.7_CD g_NN of_IN yeast_NN nitrogen_NN base_NN without_IN amino_NN acids_NNS [_SYM Difco_NP ]_SYM ,_, 20_CD g_NN of_IN glucose_NN ,_, 15_CD g_NN of_IN Bacto_NP agar_NN [_SYM Difco_NP ]_SYM ,_, and_CC 50_CD mg_NN [_SYM each_RB ]_SYM of_IN uracil_NN ,_, lysine_NN ,_, adenine_NN ,_, tryptophan_NN ,_, and_CC histidine_NN [_SYM Sigma-Aldrich_NP ]_SYM per_FW liter_NN )_) ._SENT For_IN induction_NN of_IN the_DT SAP2_NP promoter_NN and_CC excision_NN of_IN the_DT mycophenolic_JJ acid_NN (_( MPA_NP )_) resistance_NN flipper_NN cassette_NN (_( MPAR-flipper_NP )_) ,_, cells_NNS were_VBD grown_VBN in_IN YCB-BSA_NP medium_NN (_( 23.4_CD g_NN of_IN yeast_NN carbon_NN base_NN [_SYM Difco_NP ]_SYM ,_, 4_CD g_NN of_IN bovine_JJ serum_NN albumin_NN [_SYM Sigma-Aldrich_NP ]_SYM per_FW liter_NN [_SYM pH_NN 4.0_CD ]_SYM )_) ._SENT Antifungal_JJ drug_NN susceptibility_NN testing_NN ._SENT |_SYM Susceptibility_NN testing_NN of_IN C._NP dubliniensis_NN clinical_JJ isolates_NNS and_CC their_PP$ derivatives_NNS to_TO antifungal_JJ drugs_NNS and_CC metabolic_JJ inhibitors_NNS was_VBD performed_VBN by_IN using_VBG a_DT broth_NN microdilution_NN assay_NN based_VBN on_IN the_DT approved_VBN NCCLS_NP procedure_NN ._SENT Susceptibility_NN tests_NNS were_VBD carried_VBN out_RP in_IN RPMI_NP 1640_CD medium_NN (_( 10.4_CD g_NN of_IN RPMI_NP 1640_CD [_SYM Sigma-Aldrich_NP ]_SYM ,_, 20_CD g_NN of_IN glucose_NN ,_, 34.5_CD g_NN of_IN morpholinepropanesulfonic_JJ acid_NN [_SYM pH_NN 7.0_CD ]_SYM per_FW liter_NN )_) as_IN described_VBN by_IN Moran_NP et_FW al._FW ._SENT Metabolic_JJ inhibitors_NNS were_VBD purchased_VBN from_IN Sigma-Aldrich_NP ,_, fluconazole_NN was_VBD a_DT gift_NN from_IN Pfizer_NP Central_NP Research_NP (_( Sandwich_NP ,_, Kent_NP ,_, United_NP Kingdom_NP )_) ,_, and_CC itraconazole_NN and_CC ketoconazole_NN were_VBD gifts_NNS from_IN Janssen_NP Pharmaceutical_NP (_( Cork_NP ,_, Republic_NP of_IN Ireland_NP )_) ._SENT The_DT following_VBG antifungal_JJ drugs_NNS and_CC metabolic_JJ inhibitors_NNS were_VBD prepared_VBN as_IN stock_NN solutions_NNS in_IN water_NN at_IN the_DT concentrations_NNS indicated_VBD :_: fluconazole_NN ,_, 5_CD mg/ml_NN ;_: fluphenazine_NN ,_, 20_CD mg/ml_NN ;_: and_CC rhodamine_NN 6G_JJ ,_, 5_CD mg/ml_NN ._SENT Stock_NN solutions_NNS of_IN other_JJ drugs_NNS were_VBD prepared_VBN in_IN dimethyl_NN sulfoxide_NN at_IN the_DT concentrations_NNS indicated_VBD :_: ketoconazole_NN ,_, 1_CD mg/ml_NN ;_: itraconazole_NN ,_, 1_CD mg/ml_NN ;_: cycloheximide_NN ,_, 20_CD mg/ml_NN ;_: cerulenin_NN ,_, 1_CD mg/ml_NN ;_: and_CC brefeldin_NP A_NP ,_, 5_CD mg/ml_NN ._SENT Crystal_NN violet_NN (_( 2_CD mg/ml_NN )_) was_VBD dissolved_VBN in_IN methanol_NN ._SENT Stock_NN solutions_NNS of_IN drugs_NNS were_VBD diluted_VBN in_IN RPMI_NP 1640_CD medium_NN to_TO the_DT following_VBG concentrations_NNS ,_, from_IN which_WDT serial_JJ twofold_JJ dilutions_NNS were_VBD prepared_VBN in_IN 96-well_NN microtiter_NN dishes_NNS (_( Corning_NP )_) :_: fluconazole_NN ,_, 64_CD mug/ml_NN ;_: itraconazole_NN ,_, 4_CD mug/ml_NN ;_: ketoconazole_NN ,_, 2_CD mug/ml_NN ;_: cerulenin_NN ,_, 64_CD mug/ml_NN ;_: rhodamine_NN 6G_JJ ,_, 16_CD mug/ml_NN ;_: cycloheximide_NN ,_, 512_CD mug/ml_NN ;_: brefeldin_NP A_NP ,_, 512_CD mug/ml_NN ;_: and_CC fluphenazine_NN ,_, 128_CD mug/ml_NN ._SENT PCR_NP amplification_NN of_IN C._NP dubliniensis_NN CdCDR1_JJ alleles_NNS ._SENT |_SYM Amplification_NP of_IN CdCDR1_NP and_CC CdCDR2_NP genes_NNS was_VBD carried_VBN out_RP by_IN using_VBG the_DT Expand_NP high-fidelity_JJ PCR_NP system_NN (_( Roche_NP Molecular_NP Biochemicals_NP )_) ._SENT To_TO amplify_VB the_DT entire_JJ C._NP dubliniensis_NN CdCDR1_NP open_JJ reading_NN frame_NN (_( ORF_NP )_) ,_, the_DT oligonucleotide_NN primer_NN pair_NN 1F-1R_NP (_( Table_NP ;_: Fig._NN )_) was_VBD designed_VBN based_VBN on_IN the_DT nucleotide_NN sequence_NN of_IN the_DT C._NP albicans_NP CDR1_NP gene_NN ._SENT Similarly_RB ,_, for_IN amplification_NN of_IN the_DT CdCDR2_NP ORF_NP ,_, the_DT primer_JJR pair_NN 8F-8R_NN was_VBD designed_VBN based_VBN on_IN the_DT nucleotide_NN sequence_NN of_IN the_DT C._NP albicans_NP CDR2_NP gene_NN ._SENT These_DT primers_NNS contained_VBD cleavage_NN sites_NNS for_IN the_DT restriction_NN endonuclease_NN XbaI_NP ._SENT Template_NN DNA_NN was_VBD isolated_VBN from_IN C._NP dubliniensis_NN isolates_VBZ as_RB described_VBN by_IN Sullivan_NP et_FW al._FW ._SENT Sequences_NNS flanking_VBG the_DT CdCDR1_NP and_CC CdCDR2_NP genes_NNS were_VBD amplified_VBN from_IN the_DT C._NP dubliniensis_NN type_NN strain_NN CD36_NN by_IN inverse_JJ PCR_NP ._SENT Briefly_RB ,_, PCR_NP amplification_NN was_VBD carried_VBN out_RP under_IN the_DT same_JJ conditions_NNS with_IN self-ligated_JJ EcoRI-digested_JJ total_JJ genomic_JJ DNA_NN as_IN template_NN ._SENT The_DT 5_CD '_POS flanking_VBG region_NN of_IN the_DT CdCDR1_NP gene_NN was_VBD amplified_VBN with_IN the_DT oligonucleotide_NN primer_NN pair_NN 3F-3R_NN ,_, which_WDT contained_VBD the_DT EcoRI_NP restriction_NN endonuclease_NN recognition_NN sequence_NN (_( Table_NP ;_: Fig._NN )_) ._SENT The_DT 3_CD '_POS region_NN of_IN the_DT CdCDR1_NP gene_NN was_VBD amplified_VBN with_IN the_DT oligonucleotide_NN primer_NN pair_NN 4F-4R_NP (_( Table_NP ;_: Fig._NN )_) ._SENT Similarly_RB ,_, the_DT 5_CD '_POS and_CC 3_CD '_'' flanking_VBG sequences_NNS of_IN the_DT CdCDR2_NP gene_NN were_VBD amplified_VBN with_IN the_DT oligonucleotide_NN primer_NN pairs_NNS 9F-9R_NP and_CC 10F-10R_NP ,_, respectively_RB ._SENT PCR_NP products_NNS were_VBD purified_VBN from_IN the_DT reaction_NN mixture_NN by_IN using_VBG the_DT Wizard_NP PCR_NP system_NN (_( Promega_NP )_) ._SENT PCR_NP primers_NNS were_VBD designed_VBN with_IN restriction_NN endonuclease_NN recognition_NN sequences_NNS at_IN their_PP$ 5_CD '_POS ends_NNS that_IN allowed_VBN PCR_NP products_NNS to_TO be_VB digested_VBN and_CC ligated_VBN directly_RB to_TO the_DT plasmid_NP vector_NN pBluescript_NN II_NP KS(-)_NP ,_, transformed_VBN into_IN Escherichia_NP coli_NNS DH5alpha_NP as_RB described_VBD previously_RB ,_, and_CC subjected_VBN to_TO DNA_NP sequence_NN analysis_NN ._SENT Heterologous_JJ expression_NN of_IN CdCDR_NP genes_NNS in_IN S._NP cerevisiae_NNS ._SENT |_SYM The_DT oligonucleotide_NN primer_NN pairs_NNS 1F-1R_NP and_CC 8F-8R_NP (_( Table_NP ;_: Fig._NN )_) were_VBD used_VBN to_TO amplify_VB the_DT entire_JJ CdCDR1_NP and_CC CdCDR2_NP ORFs_NP ,_, respectively_RB ._SENT The_DT CdCDR1_NP and_CC CdCDR2_NP ORFs_NP were_VBD amplified_VBN from_IN genomic_JJ DNA_NN purified_VBN from_IN C._NP dubliniensis_NN isolates_VBZ CD36_NP ,_, CD57_NP ,_, CD51-II_NP ,_, CD47-IIb_NP ,_, CM1_NP ,_, and_CC CM2_NP and_CC C._NP albicans_NNS strain_VBP CA132A_NP ._SENT These_DT products_NNS were_VBD cloned_VBN by_IN using_VBG standard_JJ techniques_NNS into_IN the_DT XbaI_NP site_NN of_IN the_DT expression_NN plasmid_NN pYES_NNS and_CC transformed_VBN into_IN the_DT Deltapdr5_NP S._NP cerevisiae_NNS strain_VBP YKKB-13_NP as_RB described_VBD by_IN Sanglard_NP et_FW al._FW ._SENT Transformants_NNS of_IN YKKB-13_NP were_VBD selected_VBN on_IN minimal_JJ medium_NN without_IN uracil_NN ._SENT In_IN order_NN to_TO induce_VB expression_NN from_IN the_DT GAL1_JJ promoter_NN of_IN pYES_NNS ,_, transformants_NNS were_VBD subsequently_RB maintained_VBN on_IN minimal_JJ medium_NN without_IN uracil_NN containing_VBG 2_CD %_NN (_( wt/vol_NN )_) galactose_NN as_IN the_DT sole_JJ carbon_NN source_NN ._SENT S._NP cerevisiae_NNS transformants_NNS were_VBD tested_VBN for_IN susceptibility_NN to_TO antifungal_JJ drugs_NNS and_CC metabolic_JJ inhibitors_NNS on_IN minimal_JJ medium_NN containing_VBG galactose_NN as_IN described_VBN by_IN Sanglard_NP et_FW al._FW ._SENT Briefly_RB ,_, a_DT suspension_NN (_( 2_CD x_SYM 107_CD CFU/ml_NN )_) of_IN each_DT transformant_NN to_TO be_VB tested_VBN was_VBD prepared_VBN in_IN sterile_JJ saline_NN ._SENT This_DT solution_NN was_VBD then_RB serially_RB diluted_VBN 10-fold_NN ,_, and_CC 5_CD mul_NN of_IN each_DT dilution_NN was_VBD spotted_VBN onto_IN plates_NNS containing_VBG fixed_VBN concentrations_NNS of_IN each_DT metabolic_JJ inhibitor_NN (_( see_VB Fig._NN )_) ._SENT Susceptibility_NN to_TO each_DT drug_NN was_VBD determined_VBN based_VBN on_IN the_DT highest_JJS dilution_NN of_IN each_DT culture_NN which_WDT could_MD grow_VB in_IN the_DT presence_NN of_IN the_DT inhibitor_NN as_IN described_VBN by_IN Sanglard_NP et_FW al._FW ._SENT Western_JJ immunoblotting_NN ._SENT |_SYM Crude_JJ protein_NN extracts_VBZ were_VBD prepared_VBN from_IN C._NP dubliniensis_NN isolates_NNS ,_, resolved_VBN by_IN sodium_NN dodecyl_NN sulfate-polyacrylamide_NN gel_NN electrophoresis_NN (_( SDS-PAGE_NP )_) ,_, and_CC subjected_VBN to_TO Western_JJ immunoblot_NN analysis_NN with_IN anti-Cdr1p_JJ polyclonal_JJ sera_NN (_( a_DT gift_NN from_IN D._NP Sanglard_NP )_) as_IN described_VBN by_IN Moran_NP et_FW al._FW ._SENT Antibody-protein_NN complexes_NNS were_VBD detected_VBN with_IN the_DT SuperSignal_NP West_NP Pico_NP chemiluminescent_JJ substrate_NN (_( Pierce_NP ,_, Rockford_NP ,_, Ill._NP )_) ._SENT Molecular_JJ sizes_NNS of_IN protein_NN bands_NNS were_VBD estimated_VBN by_IN using_VBG the_DT Bio-Rad_NP broad-range_NN SDS-PAGE_NN standards_NNS (_( Bio-Rad_NP )_) and_CC the_DT GelWorks_NP one-dimensional_JJ gel_NN analysis_NN software_NN package_NN (_( UVP_NP ,_, Irvine_NP ,_, Calif._NP )_) ._SENT Site-directed_JJ mutagenesis_NN ._SENT |_SYM Site-directed_NP mutagenesis_NN was_VBD carried_VBN out_RP by_IN using_VBG the_DT GeneEditor_NP system_NN (_( Promega_NP )_) ._SENT Alleles_NNS of_IN CdCDR1_NP for_IN mutagenization_NN were_VBD subcloned_VBN into_IN the_DT plasmid_NP vector_NN pGEM-11Z(f+_NN )_) ._SENT Point_NN mutations_NNS were_VBD introduced_VBN by_IN hybridization_NN with_IN the_DT 5'-phosphorylated_JJ mutagenic_JJ oligonucleotide_NN 5'-GCTTACCAATATTATAATTC_NN ,_, which_WDT contained_VBD a_DT single_JJ G_NN to_TO T_NN substitution_NN (_( underlined_VBN )_) ,_, according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._SENT Mutant_JJ alleles_NNS were_VBD sequenced_VBN on_IN both_DT strands_NNS in_IN order_NN to_TO confirm_VB the_DT introduction_NN of_IN the_DT desired_VBN mutation_NN ._SENT Isolation_NN of_IN total_JJ RNA_NP from_IN C._NP dubliniensis_NN and_CC Northern_JJ blot_NN analysis_NN ._SENT |_SYM Total_NP RNA_NP was_VBD isolated_VBN from_IN C._NP dubliniensis_NN isolates_NNS grown_VBN to_TO the_DT mid-exponential_JJ phase_NN (_( optical_JJ density_NN at_IN 600_CD nm_NN ,_, 0.6_CD )_) in_IN YEPD_JJ broth_NN at_IN 37C_JJ as_RB described_VBN by_IN Moran_NP et_FW al._FW ._SENT RNA_NP was_VBD fractionated_VBN on_IN 1.2_CD %_NN (_( wt/vol_NN )_) agarose_NN gels_NNS containing_VBG 6_CD %_NN (_( vol/vol_NN )_) formaldehyde_NN and_CC transferred_VBN to_TO nylon_NN membranes_NNS (_( Osmonics_NP ,_, Westborough_NP ,_, Mass._NP )_) by_IN capillary_JJ transfer_NN ._SENT RNA_NP was_VBD hybridized_VBN at_IN 42C_JJ with_IN DNA_NN probes_NNS homologous_JJ to_TO CdCDR1_NP ,_, CdMDR1_NP ,_, and_CC CdTEF3_NP labeled_VBD with_IN [_SYM alpha-32P]dATP_NN (_( 6,000_CD Ci/mmol_NP ,_, 220_CD TBq/mmol_NN ;_: NEN_NP Life_NP Sciences_NPS ,_, Boston_NP ,_, Mass._NP )_) by_IN random_JJ primer_NN labeling_VBG as_IN described_VBN by_IN Moran_NP et_FW al._FW ._SENT A_DT CdCDR1-specific_NP probe_NN was_VBD constructed_VBN by_IN PCR_NP amplification_NN of_IN the_DT 5_CD '_POS region_NN of_IN the_DT CdCDR1_JJ gene_NN (_( nucleotides_NNS +1_JJ to_TO +421_JJ )_) with_IN the_DT primer_JJR pair_NN 1F-7R_NN ._SENT Similarly_RB ,_, a_DT 418-bp_JJ CdCDR2-specific_JJ probe_NN (_( nucleotides_NNS +1_JJ to_TO +418_NN )_) was_VBD amplified_VBN from_IN C._NP dubliniensis_NN genomic_JJ DNA_NN by_IN using_VBG the_DT primer_JJR pair_NN 8F-7R_NN ._SENT A_DT CdTEF3-specific_NP probe_NN was_VBD created_VBN by_IN amplification_NN of_IN an_DT internal_JJ fragment_NN of_IN the_DT CdTEF3_NP gene_NN with_IN the_DT primer_NN pair_NN TEF3F-TEF3R_NP ._SENT Signals_NNS from_IN Northern_JJ blot_NN autoradiograms_NNS were_VBD quantified_VBN by_IN scanning_VBG densitometry_NN and_CC normalized_VBN for_IN loading_VBG against_IN the_DT CdTEF3_NP expression_NN signal_NN with_IN the_DT Gelworks_NP one-dimensional_JJ software_NN package_NN (_( UVP_NP )_) ._SENT Targeted_JJ disruption_NN of_IN the_DT CdCDR1_JJ gene_NN ._SENT |_SYM Targeted_JJ disruption_NN of_IN the_DT CdCDR1_JJ gene_NN in_IN C._NP dubliniensis_NP CD57R_NP was_VBD carried_VBN out_RP by_IN using_VBG the_DT MPAR-flipper_NP technique_NN ._SENT Two_CD different_JJ deletion_NN constructs_NNS were_VBD made_VBN to_TO inactivate_VB both_DT alleles_NNS of_IN the_DT CdCDR1_JJ gene_NN ._SENT To_TO create_VB the_DT first_JJ construct_NN ,_, the_DT entire_JJ CdCDR1_NP ORF_NP was_VBD cloned_VBN in_IN the_DT XbaI_NP site_NN of_IN pUC19_NN ._SENT A_DT deletion_NN was_VBD created_VBN in_IN this_DT clone_NN by_IN inverse_JJ PCR_NP with_IN the_DT primer_NN pair_NN 5F-5R_NP (_( Table_NP ;_: Fig._NN )_) ._SENT This_DT allowed_VBN amplification_NN of_IN the_DT 5_CD '_POS and_CC 3_CD '_'' ends_NNS of_IN the_DT CdCDR1_NP ORF_NP and_CC the_DT entire_JJ plasmid_NN vector_NN ._SENT These_DT primers_NNS contained_VBD SacII_NP and_CC XhoI_NP restriction_NN endonuclease_NN recognition_NN sequences_NNS that_WDT enabled_VBD the_DT insertion_NN of_IN the_DT SacII/XhoI_NP fragment_NN of_IN pSFI1_JJ (_( containing_VBG the_DT site-specific_JJ recombinase_NN FLP_NP and_CC the_DT MPA_NP resistance_NN gene_NN )_) ,_, thereby_RB replacing_VBG the_DT central_JJ region_NN of_IN the_DT CdCDR1_NP ORF_NP to_TO create_VB plasmid_NN pCDRDelta1_NN ._SENT To_TO create_VB the_DT second_JJ construct_NN ,_, the_DT internal_JJ AccI/BamHI_NP fragment_NN of_IN CdCDR1_NP was_VBD cloned_VBN into_IN pUC19_NN and_CC subjected_VBN to_TO inverse_JJ PCR_NP with_IN the_DT primer_NN pair_NN 6F-6R_NP (_( Table_NP ;_: Fig._NN )_) ._SENT This_DT product_NN was_VBD also_RB ligated_VBN with_IN the_DT SacII/XhoI_NP fragment_NN from_IN pSFI1_NN to_TO create_VB the_DT plasmid_NN pCDRDelta2_NN ._SENT C._NP dubliniensis_NN was_VBD sequentially_RB transformed_VBN by_IN using_VBG approximately_RB 1_CD mug_NN of_IN the_DT linear_JJ SacI/SphI_NP fragments_NNS from_IN plasmids_NNS pCDRDelta1_JJ and_CC pCDRDelta2_JJ by_IN electroporation_NN as_IN described_VBN by_IN Staib_NP et_FW al._FW ._SENT MPA-resistant_JJ transformants_NNS were_VBD selected_VBN on_IN minimal_JJ medium_JJ agar_NN plates_NNS containing_VBG 10_CD ,_, 15_CD ,_, or_CC 20_CD mug_NN of_IN MPA_NP per_IN ml_NN ._SENT Isolation_NN of_IN genomic_JJ DNA_NP and_CC Southern_NP blotting_VBG ._SENT |_SYM Genomic_NP DNA_NP from_IN C._NP dubliniensis_NN isolates_NNS and_CC derivatives_NNS for_IN use_NN in_IN PCR_NP and_CC Southern_NP blotting_VBG experiments_NNS was_VBD isolated_VBN by_IN using_VBG the_DT method_NN of_IN Sullivan_NP et_FW al._FW ._SENT For_IN Southern_NP blotting_VBG ,_, 10_CD mug_NN of_IN genomic_JJ DNA_NN was_VBD digested_VBN with_IN the_DT appropriate_JJ restriction_NN endonuclease_NN and_CC separated_VBN on_IN 0.8_CD %_NN (_( wt/vol_NN )_) agarose_NN gels_NNS ._SENT DNA_NP was_VBD transferred_VBN to_TO nylon_NN membranes_NNS (_( Osmonics_NP )_) by_IN capillary_JJ transfer_NN overnight_RB ._SENT Hybridization_NN was_VBD carried_VBN out_RP under_IN high-stringency_NN conditions_NNS by_IN standard_JJ techniques_NNS with_IN DNA_NN probes_NNS labeled_VBN with_IN alpha-32P_NN by_IN random_JJ primer_NN labeling_VBG ._SENT FIG._NN 1_CD ._SENT |_SYM Restriction_NN map_NN of_IN CdCDR1_NP (_( A_NP )_) and_CC CdCDR2_NP (_( B_NP )_) encoding_VBG DNA_NN from_IN C._NP dubliniensis_NN Restriction_NN map_NN of_IN CdCDR1_NP (_( A_NP )_) and_CC CdCDR2_NP (_( B_NP )_) encoding_VBG DNA_NN from_IN C._NP dubliniensis_NN CD36_NP ._SENT The_DT black_JJ rectangular_JJ boxes_NNS represent_VBP C._NP dubliniensis_NN genomic_JJ DNA_NN which_WDT was_VBD amplified_VBN by_IN PCR_NP from_IN genomic_JJ DNA_NN (_( see_VB Materials_NNS and_CC Methods_NNS )_) ._SENT The_DT large_JJ arrows_NNS show_VBP the_DT positions_NNS and_CC directions_NNS of_IN transcription_NN of_IN the_DT CdCDR1_NP and_CC CdCDR2_NP ORFs_NP ._SENT The_DT asterisk_NN in_IN the_DT CdCDR1_NP ORF_NP shows_VBZ the_DT position_NN of_IN the_DT polymorphic_JJ codon_NN 756_CD ._SENT The_DT approximate_JJ positions_NNS of_IN the_DT CdCDR1-_NP and_CC CdCDR2-specific_NP PCR_NP primers_NNS shown_VBN in_IN Table_NP are_VBP indicated_VBN by_IN small_JJ arrows_NNS ._SENT Primer_NP pairs_NNS 5F-5R_NP and_CC 6F-6R_NP shown_VBN at_IN the_DT bottom_NN of_IN panel_NN A_DT were_VBD used_VBN in_IN the_DT inverse_JJ PCR_NP experiments_NNS performed_VBD to_TO disrupt_VB the_DT CdCDR1_JJ gene_NN ._SENT Restriction_NN endonuclease_NN cleavage_NN sites_NNS :_: A_DT ,_, AccI_NP ;_: B_NP ,_, BamHI_NP ;_: E_NP ,_, EcoRI_NP ;_: P_NN ,_, PvuII_NP ._SENT FIG._NN 3_CD ._SENT |_SYM Susceptibility_NP of_IN S._NP cerevisiae_NNS Susceptibility_NN of_IN S._NP cerevisiae_NP YKKB-13_NP (_( pdr5_NN )_) transformants_NNS harboring_VBG cloned_VBN CDR1_JJ genes_NNS to_TO antifungal_JJ drugs_NNS and_CC metabolic_JJ inhibitors_NNS ._SENT (_( A_NP )_) CDR1_JJ alleles_NNS from_IN C._NP albicans_NP and_CC C._NP dubliniensis_NN isolates_NNS were_VBD amplified_VBN by_IN PCR_NP ,_, cloned_VBN into_IN the_DT GAL1_NP expression_NN vector_NN pYES_NNS and_CC transformed_VBN into_IN the_DT S._NP cerevisiae_NNS strain_VBP YKKB-13_NP ._SENT The_DT transformants_NNS harbored_VBD the_DT pYES_NP plasmid_NP (_( Vector_NP )_) ,_, cloned_VBN CDR1_NP from_IN C._NP albicans_NP CA132A_NP (_( Y132A_NP )_) ,_, and_CC cloned_VBN CdCDR1_JJ genes_NNS from_IN the_DT C._NP dubliniensis_NN isolates_VBZ CD36_NP (_( YCD36_NP )_) ,_, CD57_JJ (_( YCD57_JJ )_) ,_, and_CC CD51-II_NP (_( YCD51-II_NP )_) ._SENT A_DT suspension_NN (_( 2_CD x_SYM 107_CD CFU/ml_NN )_) of_IN each_DT transformant_NN was_VBD serially_RB diluted_VBN ,_, and_CC 5_CD mul_NN of_IN each_DT dilution_NN was_VBD spotted_VBN onto_IN minimal_JJ agar_NN medium_NN plates_NNS containing_VBG fixed_VBN concentrations_NNS of_IN the_DT antifungal_JJ drug_NN or_CC metabolic_JJ inhibitor_NN indicated_VBD ._SENT (_( B_NP )_) Fluconazole_NP susceptibility_NN of_IN YKKB-13_NP transformants_NNS harboring_VBG the_DT cloned_VBN C._NP albicans_NP CA132A_NP CDR1_NP gene_NN (_( Y132A_NP )_) ,_, the_DT CD36_NP CdCDR1_NP gene_NN (_( YCD36_NP )_) ,_, and_CC the_DT mutated_VBN CD36_NP CdCDR1_NP gene_NN (_( YMCD36_NP )_) in_IN which_WDT the_DT premature_JJ stop_NN codon_NN has_VBZ been_VBN reassigned_VBN ._SENT TABLE_NN 1_CD |_SYM Candida_NP strains_NNS and_CC derivatives_NNS used_VBN in_IN this_DT study_NN TABLE_NP 2_CD |_SYM Oligonucleotide_NN primers_NNS used_VBN in_IN PCRs_JJ Isolation_NN and_CC sequence_NN analysis_NN of_IN CdCDR1_NP ._SENT |_SYM In_IN order_NN to_TO isolate_VB the_DT C._NP dubliniensis_NN homologue_NN of_IN the_DT C._NP albicans_NP CDR1_NP gene_NN ,_, a_DT 6,848-bp_JJ region_NN of_IN C._NP dubliniensis_NN chromosomal_JJ DNA_NN was_VBD PCR_NP amplified_VBN by_IN using_VBG a_DT high-fidelity_JJ polymerase_NN mixture_NN from_IN genomic_JJ DNA_NN isolated_VBN from_IN the_DT C._NP dubliniensis_NN type_NN strain_NN CD36_NP (_( CBS_NP 7987_CD )_) ._SENT Initially_RB ,_, the_DT primer_NN pair_NN 1F-1R_NP (_( Table_NP ;_: Fig._NN )_) ,_, which_WDT was_VBD designed_VBN to_TO amplify_VB the_DT entire_JJ C._NP albicans_NNS CDR1_NP ORF_NP ,_, was_VBD used_VBN to_TO amplify_VB a_DT 4,506-bp_JJ region_NN of_IN C._NP dubliniensis_NN genomic_JJ DNA_NN corresponding_JJ to_TO the_DT putative_JJ C._NP dubliniensis_NN CDR1_NP homologue_NN ._SENT The_DT nucleotide_NN sequences_NNS 5_CD '_'' and_CC 3_CD '_'' to_TO this_DT region_NN were_VBD then_RB amplified_VBN from_IN C._NP dubliniensis_NN CD36_NP genomic_JJ DNA_NN by_IN an_DT inverse_JJ PCR_NP method_NN with_IN the_DT primer_NN pairs_NNS 3F-3R_NP and_CC 4F-4R_NP (_( Table_NP ;_: Fig._NN )_) ,_, respectively_RB ._SENT Using_VBG this_DT strategy_NN ,_, a_DT 614-bp_JJ region_NN upstream_RB of_IN the_DT putative_JJ CdCDR1_NP ORF_NP and_CC a_DT 1,728-bp_JJ downstream_JJ region_NN were_VBD amplified_VBN from_IN C._NP dubliniensis_NN CD36_NP chromosomal_JJ DNA_NN ._SENT The_DT entire_JJ amplified_VBN chromosomal_JJ DNA_NN region_NN from_IN strain_NN CD36_NP was_VBD then_RB sequenced_JJ on_IN both_DT strands_NNS ._SENT The_DT putative_JJ CdCDR1_NP ORF_NP amplified_VBD with_IN the_DT primer_NN pair_NN CDR1F-CDR1R_NP was_VBD 4,506_CD bp_NN in_IN length_NN and_CC was_VBD 92_CD %_NN identical_JJ at_IN the_DT nucleotide_NN sequence_NN level_NN to_TO the_DT C._NP albicans_NP CDR1_NP ORF_NP ._SENT The_DT 614-bp_JJ 5'-flanking_JJ region_NN of_IN this_DT sequence_NN shared_VBD 46.6_CD %_NN identity_NN at_IN the_DT nucleotide_NN sequence_NN level_NN with_IN the_DT C._NP albicans_NP CDR1_NP promoter_NN and_CC contains_VBZ a_DT putative_JJ TATA_NP box_NN at_IN nucleotide_NN position_NN -126_CD (_( the_DT first_JJ base_NN of_IN the_DT ATG_NP start_NN codon_NN was_VBD designated_VBN +1_JJ )_) ._SENT In_IN addition_NN ,_, the_DT C._NP dubliniensis_NN promoter_NN sequence_NN contains_VBZ a_DT motif_NN at_IN the_DT nucleotide_NN coordinates_VBZ -371_CD to_TO -350_CD (_( 5'-CGGTTATCGGATATTTTTTTT_NP )_) matching_VBG the_DT drug_NN response_NN element_NN (_( DRE_NP )_) in_IN C._NP albicans_NNS ._SENT The_DT 3'-flanking_JJ region_NN of_IN the_DT putative_JJ CdCDR1_NP ORF_NP also_RB contained_VBD sequences_NNS homologous_JJ to_TO the_DT C._NP albicans_NP SAP3_NP gene_NN encoding_VBG a_DT member_NN of_IN the_DT secreted_VBN aspartyl-proteinase_NN family_NN ,_, which_WDT we_PP have_VBP termed_VBN CdSAP3_NP ._SENT This_DT is_VBZ the_DT same_JJ gene_NN order_NN as_RB observed_VBD in_IN the_DT C._NP albicans_NNS genome_NN ._SENT However_RB ,_, comparison_NN of_IN the_DT C._NP albicans_NP and_CC C._NP dubliniensis_NN CDR1_NP ORFs_NP revealed_VBD that_IN the_DT C._NP dubliniensis_NN CD36_NP CdCDR1_NP gene_NN contained_VBD a_DT TAG_NP translation_NN stop_NN codon_NN at_IN the_DT nucleotide_NN coordinates_VBZ +2266_NN to_TO +2268_NP (_( codon_NN 756_CD )_) which_WDT corresponded_VBD to_TO a_DT single_JJ base_NN difference_NN (_( G_NN to_TO T_NN )_) that_WDT converted_VBD the_DT tyrosine_NN (Y756)-encoding_VBG TAT_NP codon_NN found_VBD in_IN the_DT C._NP albicans_NP CDR1_NP gene_NN to_TO a_DT TAG_NP translation_NN stop_NN signal_NN ._SENT The_DT predicted_VBN polypeptide_NN encoded_VBN by_IN this_DT shorter_JJR ORF_NP was_VBD 755_CD amino_NN acids_NNS in_IN length_NN and_CC had_VBD a_DT predicted_VBN molecular_JJ mass_NN of_IN 85_CD kDa_NNS ;_: the_DT C._NP albicans_NNS protein_NN is_VBZ 1,501_CD amino_NN acids_NNS in_IN length_NN and_CC has_VBZ a_DT predicted_VBN molecular_JJ mass_NN of_IN 168_CD kDa_NN ._SENT The_DT truncated_JJ CdCdr1p_NN was_VBD 96.7_CD %_NN identical_JJ to_TO the_DT corresponding_JJ amino_NN acid_NN sequences_NNS of_IN CaCdr1p_NP ._SENT In_IN order_NN to_TO confirm_VB that_IN this_DT substitution_NN was_VBD not_RB a_DT PCR_NP artifact_NN ,_, this_DT region_NN was_VBD sequenced_VBN in_IN six_CD clones_NNS generated_VBN in_IN six_CD separate_JJ PCR_NP amplifications_NNS and_CC an_DT identical_JJ nucleotide_NN sequence_NN was_VBD found_VBN in_IN each_DT clone_NN ._SENT These_DT data_NNS strongly_RB suggested_VBD that_IN the_DT substitution_NN was_VBD present_JJ in_IN both_DT alleles_NNS of_IN CdCDR1_NP ._SENT Identification_NN of_IN polymorphic_JJ alleles_NNS of_IN CdCDR1_NP ._SENT |_SYM In_IN order_NN to_TO determine_VB whether_IN other_JJ strains_NNS of_IN C._NP dubliniensis_NN harbored_VBD the_DT TAG_NP nonsense_NN codon_NN ,_, the_DT region_NN of_IN the_DT CdCDR1_NP ORF_NP containing_VBG codon_NN 756_CD was_VBD sequenced_VBN in_IN C._NP dubliniensis_NN isolates_VBZ CM1_NP ,_, CM2_NP ,_, CD57_NP ,_, CD51-II_NP ,_, and_CC CD47-IIb_NP ._SENT In_IN order_NN to_TO achieve_VB this_DT ,_, a_DT 490-bp_JJ region_NN of_IN the_DT CdCDR1_NP ORF_NP was_VBD amplified_VBN by_IN PCR_NP with_IN the_DT primer_NN pair_NN 2F-2R_NP (_( Table_NP ;_: Fig._NN )_) ._SENT This_DT amplified_VBN product_NN encompassed_VBD the_DT nucleotide_NN region_NN +2071_JJ to_TO +2557_JJ of_IN the_DT CdCDR1_NP ORF_NP ,_, including_VBG the_DT TAG_NP codon_NN at_IN the_DT nucleotide_NN coordinates_VBZ +2266_NN to_TO +2268_NN in_IN C._NP dubliniensis_NN strain_NN CD36_NP ._SENT Nucleotide_NN sequence_NN analysis_NN of_IN this_DT region_NN demonstrated_VBD that_IN C._NP dubliniensis_NN isolates_VBZ CD51-II_NP and_CC CD47-IIb_NP harbor_VBP a_DT nonsense_JJ mutation_NN identical_JJ to_TO that_DT found_VBN in_IN the_DT CdCDR1_NP ORF_NP of_IN isolate_NN CD36_NP ._SENT However_RB ,_, isolates_VBZ CD57_JJ ,_, CM1_NP ,_, and_CC CM2_NP contained_VBD a_DT tyrosine_NN codon_NN identical_JJ to_TO that_DT found_VBN in_IN the_DT C._NP albicans_NP CDR1_NP ORF_NP ._SENT The_DT entire_JJ nucleotide_NN sequence_NN of_IN the_DT CdCDR1_JJ gene_NN from_IN C._NP dubliniensis_NN CD57_JJ was_VBD determined_VBN in_IN order_NN to_TO compare_VB the_DT sequence_NN of_IN a_DT gene_NN without_IN the_DT nonsense_JJ mutation_NN with_IN that_IN from_IN strain_NN CD36_NP ._SENT The_DT nucleotide_NN sequence_NN of_IN the_DT C._NP dubliniensis_NN CD57_JJ CdCDR1_NP ORF_NP was_VBD 99.7_CD %_NN identical_JJ (_( containing_VBG 9_CD base_NN differences_NNS )_) to_TO the_DT CdCDR1_NP ORF_NP from_IN strain_NN CD36_NP ._SENT The_DT predicted_VBN amino_NN acid_NN sequence_NN of_IN the_DT CD57_NP CdCdr1p_NP contained_VBD three_CD amino_NN acid_JJ substitutions_NNS (_( H60R_NP ,_, V173M_NP ,_, and_CC S1264L_NP )_) compared_VBD to_TO the_DT CD36_NP sequence_NN ._SENT However_RB ,_, the_DT predicted_VBD CdCDR1_NP ORF_NP from_IN strain_NN CD57_JJ was_VBD not_RB interrupted_VBN by_IN a_DT premature_JJ stop_NN codon_NN at_IN nucleotide_NN positions_NNS +2266_JJ to_TO +2268_NN and_CC was_VBD identical_JJ in_IN size_NN (_( 4,506_CD bp_NN )_) to_TO the_DT homologous_JJ C._NP albicans_NNS CDR1_JJ gene_NN ._SENT The_DT nucleotide_NN sequence_NN of_IN the_DT CdCDR1_NP ORF_NP from_IN strain_NN CD57_JJ was_VBD 92_CD %_NN identical_JJ to_TO the_DT corresponding_JJ sequence_NN of_IN the_DT C._NP albicans_NP CDR1_NP gene_NN ._SENT The_DT CD57_JJ CdCDR1_JJ gene_NN encodes_VBZ a_DT predicted_VBN polypeptide_NN of_IN 169.6_CD kDa_NN that_WDT is_VBZ 96.5_CD %_NN identical_JJ at_IN the_DT amino_NN acid_NN sequence_NN level_NN to_TO the_DT corresponding_JJ C._NP albicans_NNS sequence_NN ._SENT This_DT highly_RB homologous_JJ sequence_NN contained_VBD the_DT typical_JJ features_NNS described_VBN in_IN C._NP albicans_NP Cdr1p_NP ,_, namely_RB the_DT conserved_VBN Walker_NP A_NP and_CC Walker_NP B_NP motifs_NNS and_CC an_DT ATP_NP binding_JJ motif_NN in_IN the_DT N-terminal_JJ hydrophilic_JJ domain_NN ._SENT The_DT tyrosine-encoding_NN TAT_NN at_IN codon_NN position_NN 756_CD in_IN isolates_NNS CM1_NP ,_, CM2_NP ,_, and_CC CD57_JJ was_VBD found_VBN to_TO be_VB located_VBN within_IN the_DT recognition_NN sequence_NN for_IN the_DT restriction_NN endonuclease_NN SspI_NP (_( 5'-AATATT_NP )_) ._SENT This_DT SspI_NP recognition_NN sequence_NN was_VBD absent_JJ in_IN alleles_NNS from_IN CD36_NP ,_, CD51-II_NP ,_, and_CC CD47-IIb_NP containing_VBG the_DT TAG_NP stop_NN codon_NN (_( 5'-AATAGT_JJ )_) ._SENT PCR_NP products_NNS amplified_VBN from_IN isolates_NNS CM1_NP ,_, CM2_NP ,_, and_CC CD57_JJ with_IN the_DT primer_JJR pair_NN 2F-2R_NN could_MD be_VB digested_VBN with_IN the_DT restriction_NN endonuclease_NN SspI_NP to_TO yield_VB two_CD distinct_JJ fragments_NNS of_IN 200_CD and_CC 290_CD bp_NN ,_, respectively_RB ,_, in_IN agarose_JJ gels_NNS ._SENT However_RB ,_, SspI_NP digestion_NN of_IN the_DT amplified_VBN product_NN from_IN isolates_NNS CD36_NP ,_, CD51-II_NP ,_, and_CC CD47-IIb_NP ,_, which_WDT contained_VBD the_DT TAG_NP nonsense_NN codon_NN ,_, yielded_VBD a_DT single_JJ band_NN of_IN approximately_RB 500_CD bp_NN in_IN agarose_JJ gels_NNS ,_, indicating_VBG that_IN the_DT SspI_NP recognition_NN sequence_NN was_VBD absent_JJ ._SENT We_PP utilized_VBD this_DT restriction_NN fragment_NN length_NN polymorphism_NN as_IN the_DT basis_NN of_IN a_DT screening_NN assay_NN to_TO analyze_VB a_DT larger_JJR group_NN of_IN C._NP dubliniensis_NN isolates_VBZ for_IN the_DT presence_NN or_CC absence_NN of_IN the_DT nonsense_JJ mutation_NN ._SENT A_DT group_NN of_IN 40_CD C._NP dubliniensis_NN isolates_VBZ (_( all_DT isolates_NNS in_IN Table_NP ,_, excluding_VBG derivatives_NNS of_IN CD36_NP ,_, CD57_JJ ,_, and_CC CD51-II_NP )_) ,_, including_VBG representative_JJ isolates_NNS from_IN the_DT four_CD C._NP dubliniensis_NN genotypes_NNS recently_RB described_VBN by_IN Gee_NP et_FW al._FW ,_, were_VBD analyzed_VBN for_IN the_DT presence_NN of_IN the_DT TAT_NP codon_NN by_IN SspI_NP digestion_NN of_IN PCR_NP products_NNS generated_VBN from_IN these_DT isolates_NNS with_IN the_DT primer_JJR pair_NN 2F-2R_NN ._SENT This_DT analysis_NN revealed_VBD that_IN all_DT of_IN the_DT isolates_NNS tested_VBN (_( n_NN =_SYM 16_CD )_) belonging_VBG to_TO C._NP dubliniensis_NN genotypes_NNS 2_CD ,_, 3_CD ,_, and_CC 4_CD harbored_VBN CdCDR1_JJ alleles_NNS that_WDT contained_VBD the_DT TAT_NP tyrosine_NN codon_NN ,_, as_IN SspI_NP digestion_NN of_IN the_DT 2F-2R-amplified_JJ region_NN yielded_VBD two_CD fragments_NNS in_IN agarose_JJ gels_NNS ._SENT However_RB ,_, analysis_NN of_IN 24_CD genotype_NN 1_CD C._NP dubliniensis_NN isolates_NNS revealed_VBD that_DT 14_CD (_( 58_CD %_NN )_) harbored_VBD CdCDR1_JJ alleles_NNS that_WDT could_MD not_RB be_VB digested_VBN by_IN SspI_NP at_IN this_DT region_NN ._SENT DNA_NP sequence_NN analysis_NN of_IN the_DT 2F-2R-amplified_JJ region_NN from_IN these_DT 14_CD isolates_NNS revealed_VBD the_DT presence_NN of_IN a_DT TAG_NP stop_NN codon_NN that_WDT disrupted_VBD the_DT SspI_NP recognition_NN sequence_NN ._SENT These_DT data_NNS confirm_VBP that_IN the_DT premature_JJ stop_NN codon_NN is_VBZ present_JJ in_IN both_DT alleles_NNS of_IN CdCDR1_NP in_IN these_DT isolates_NNS ._SENT Two_CD of_IN these_DT isolates_NNS were_VBD found_VBN to_TO harbor_VB CdCDR1_JJ alleles_NNS containing_VBG both_CC the_DT TAT_NP and_CC TAG_NP codon_NN sequences_NNS ,_, indicating_VBG heterozygosity_NN at_IN this_DT locus_NN ._SENT In_IN total_NN ,_, 35_CD %_NN (_( 14_CD of_IN 40_CD )_) of_IN the_DT C._NP dubliniensis_NN isolates_NNS tested_VBN were_VBD found_VBN to_TO contain_VB CdCDR1_JJ alleles_NNS containing_VBG the_DT TAG_NP stop_NN codon_NN ._SENT Isolation_NN and_CC sequence_NN analysis_NN of_IN CdCDR2_NP ._SENT |_SYM In_IN order_NN to_TO isolate_VB the_DT C._NP dubliniensis_NN homologue_NN of_IN CDR2_NP ,_, the_DT primer_JJR pair_NN 8F-8R_NN was_VBD designed_VBN based_VBN on_IN the_DT nucleotide_NN sequence_NN of_IN the_DT C._NP albicans_NP CDR2_NP gene_NN ._SENT This_DT primer_NN pair_NN was_VBD used_VBN to_TO amplify_VB the_DT complete_JJ C._NP dubliniensis_NN CdCDR2_NP gene_NN from_IN the_DT genomic_JJ DNA_NN of_IN strain_NN CD36_NP ._SENT The_DT amplified_VBN CdCDR2_NP ORF_NP was_VBD 4,503_CD bp_NN in_IN length_NN ,_, which_WDT is_VBZ 3_CD bp_NN longer_JJR than_IN the_DT C._NP albicans_NP CDR2_NP ORF_NP due_JJ to_TO the_DT presence_NN of_IN an_DT additional_JJ codon_NN ._SENT The_DT C._NP dubliniensis_NN CdCDR2_NP gene_NN shared_VBD 91_CD %_NN identity_NN with_IN the_DT C._NP albicans_NP CDR2_NP ORF_NP at_IN the_DT nucleotide_NN sequence_NN level_NN ._SENT This_DT ORF_NP was_VBD preceded_VBN at_IN the_DT 5_CD '_POS end_NN by_IN a_DT TATA_NP box_NN at_IN position_NN -99_CD (_( the_DT first_JJ base_NN of_IN the_DT ATG_NP start_NN codon_NN was_VBD designated_VBN +1_JJ )_) ._SENT Like_IN CdCDR1_NP ,_, the_DT C._NP dubliniensis_NN CdCDR2_NP gene_NN was_VBD preceded_VBN by_IN a_DT DRE_NP motif_NN at_IN nucleotide_NN coordinates_VBZ -210_CD to_TO -189_CD ._SENT The_DT C._NP dubliniensis_NN CdCDR2_NP ORF_NP encodes_VBZ a_DT protein_NN with_IN a_DT predicted_VBN molecular_JJ mass_NN of_IN 168.9_CD kDa_NN that_WDT is_VBZ 94.4_CD %_NN identical_JJ at_IN the_DT amino_NN acid_NN sequence_NN level_NN to_TO the_DT corresponding_JJ C._NP albicans_NNS protein_NN ._SENT This_DT sequence_NN contained_VBD identical_JJ Walker_NP A_NP and_CC Walker_NP B_NP motifs_NNS and_CC an_DT identical_JJ ATP_NP binding_JJ motif_NN to_TO that_WDT described_VBD by_IN Sanglard_NP et_FW al._FW in_IN the_DT C._NP albicans_NP Cdr2p_NP ._SENT Western_JJ immunoblot_NN analysis_NN of_IN CdCdr1p_NP ._SENT |_SYM Crude_JJ protein_NN extracts_VBZ of_IN C._NP dubliniensis_NN were_VBD analyzed_VBN by_IN Western_JJ immunoblotting_NN with_IN polyclonal_JJ sera_NN raised_VBN against_IN the_DT N-terminal_JJ region_NN of_IN the_DT C._NP albicans_NP Cdr1p_NP ._SENT In_IN protein_NN extracts_VBZ from_IN C._NP albicans_NP CA132A_NP and_CC C._NP dubliniensis_NN isolates_VBZ CD41_NP ,_, CD57_NP ,_, CD72_NP ,_, CM1_NP ,_, and_CC CM2_NP ,_, a_DT protein_NN of_IN approximately_RB 170_CD kDa_NNS was_VBD detected_VBN ,_, matching_VBG the_DT predicted_VBN size_NN of_IN C._NP albicans_NP Cdr1p_NP and_CC the_DT protein_NN encoded_VBN by_IN the_DT full-length_JJ CdCDR1_NP ORF_NP ._SENT However_RB ,_, in_IN protein_NN extracts_VBZ from_IN C._NP dubliniensis_NN isolates_VBZ CD36_NP ,_, CD51-II_NP ,_, CD47-IIb_NP ,_, CO4_NP ,_, and_CC P30_NP ,_, whose_WP$ CdCDR1_NP ORFs_NP were_VBD found_VBN by_IN sequence_NN analysis_NN to_TO contain_VB a_DT TAG_NP translational_JJ stop_NN signal_NN at_IN codon_NN 756_CD ,_, anti-Cdr1p_NN sera_NN reacted_VBD with_IN a_DT smaller_JJR polypeptide_NN of_IN 85_CD kDa_NN ._SENT This_DT smaller_JJR protein_NN is_VBZ identical_JJ in_IN size_NN to_TO the_DT truncated_JJ protein_NN predicted_VBD from_IN the_DT CdCDR1_JJ nucleotide_NN sequence_NN obtained_VBN from_IN C._NP dubliniensis_NN strain_NN CD36_NP ._SENT Functional_JJ analysis_NN of_IN the_DT CdCDR1_NP and_CC CdCDR2_NP genes_NNS ._SENT |_SYM The_DT CdCDR1_NP and_CC CdCDR2_NP ORFs_NP were_VBD amplified_VBN from_IN genomic_JJ DNA_NN recovered_VBN from_IN C._NP dubliniensis_NN isolates_VBZ CD36_NP ,_, CD57_NP ,_, CD51-II_NP ,_, CD47-IIb_NP ,_, CM1_NP ,_, and_CC CM2_NP and_CC C._NP albicans_NNS strain_VBP CA132A_NP ._SENT Amplicons_NNS were_VBD cloned_VBN in_IN the_DT S._NP cerevisiae_NP GAL1_NP expression_NN vector_NN pYES_NNS and_CC were_VBD transformed_VBN into_IN the_DT azole-susceptible_JJ Deltapdr5_NP S._NP cerevisiae_NNS strain_VBP YKKB-13_NP ._SENT Transformants_NNS were_VBD cultured_VBN on_IN minimal_JJ agar_NN medium_NN containing_VBG 2_CD %_NN (_( wt/vol_NN )_) galactose_NN as_IN the_DT sole_JJ carbon_NN source_NN in_IN order_NN to_TO induce_VB expression_NN of_IN the_DT cloned_VBN CDR_NP genes_NNS ._SENT Northern_JJ blot_NN analysis_NN of_IN total_JJ RNA_NP from_IN galactose-grown_JJ transformants_NNS revealed_VBD high_JJ levels_NNS of_IN expression_NN of_IN the_DT mRNAs_NNS for_IN CdCDR1_NP and_CC CdCDR2_NP in_IN the_DT respective_JJ transformants_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Transformants_NNS were_VBD tested_VBN for_IN susceptibility_NN to_TO azole_NN antifungal_NN drugs_NNS and_CC metabolic_JJ inhibitors_NNS known_VBN to_TO be_VB substrates_NNS for_IN C._NP albicans_NP Cdr1p_NP and_CC Cdr2p_NP ._SENT Cloned_VBN CDR1_JJ amplicons_NNS from_IN C._NP albicans_NP CA132A_NP and_CC from_IN the_DT C._NP dubliniensis_NN isolates_VBZ CM1_NP ,_, CM2_NP ,_, and_CC CD57_JJ were_VBD found_VBN to_TO confer_VB resistance_NN to_TO fluconazole_NN and_CC itraconazole_NN and_CC to_TO the_DT metabolic_JJ inhibitors_NNS rhodamine_NN 6G_JJ ,_, cycloheximide_NN ,_, brefeldin_NP A_NP ,_, crystal_NN violet_NN ,_, and_CC cerulenin_NN in_IN S._NP cerevisiae_NP YKKB-13_NP (_( Table_NP ;_: Fig._NN )_) ._SENT However_RB ,_, CdCDR1_JJ amplicons_NNS from_IN C._NP dubliniensis_NN isolates_VBZ CD36_NP ,_, CD51-II_NP ,_, and_CC CD47-IIb_NP ,_, which_WDT encoded_VBD the_DT truncated_JJ CdCdr1p_NP ,_, did_VBD not_RB confer_VB resistance_NN to_TO any_DT of_IN these_DT compounds_NNS in_IN S._NP cerevisiae_NP YKKB-13_NP ,_, despite_IN the_DT fact_NN that_IN high_JJ levels_NNS of_IN CdCDR1_JJ mRNA_NN could_MD be_VB detected_VBN in_IN these_DT transformants_NNS by_IN Northern_JJ analysis_NN (_( data_NNS not_RB shown_VBN )_) ._SENT For_IN each_DT of_IN these_DT isolates_NNS ,_, at_IN least_JJS six_CD separate_JJ CdCDR1-encoding_NP amplicons_NNS cloned_VBN from_IN separate_JJ PCRs_NNS were_VBD analyzed_VBN and_CC identical_JJ phenotypes_NNS were_VBD obtained_VBN from_IN each_DT clone_NN ._SENT In_IN order_NN to_TO unequivocally_RB determine_VB if_IN the_DT premature_JJ translational_JJ stop_NN signal_NN at_IN codon_NN 756_CD of_IN the_DT CdCDR1_NP gene_NN was_VBD responsible_JJ for_IN the_DT loss_NN of_IN function_NN of_IN the_DT heterologously_RB expressed_VBN protein_NN in_IN S._NP cerevisiae_NNS ,_, we_PP carried_VBD out_RP site-directed_JJ mutagenesis_NN to_TO restore_VB the_DT tyrosine-encoding_JJ TAT_NP codon_NN at_IN this_DT position_NN in_IN the_DT cloned_VBN C._NP dubliniensis_NN CD36_NP CdCDR1_NP gene_NN ._SENT Reassignment_NN of_IN this_DT codon_NN fully_RB restored_VBD the_DT ability_NN of_IN the_DT expressed_VBN protein_NN to_TO impart_VB a_DT drug_NN resistance_NN phenotype_NN in_IN S._NP cerevisiae_NP YKKB-13_NP compared_VBD to_TO that_DT of_IN the_DT truncated_JJ C._NP dubliniensis_NN CdCdr1p_NP ._SENT The_DT susceptibility_NN of_IN the_DT CdCDR2-harboring_NP transformants_NNS to_TO fluconazole_NN and_CC itraconazole_NN was_VBD also_RB determined_VBN ._SENT When_WRB compared_VBN to_TO S._NP cerevisiae_NNS harboring_VBG the_DT plasmid_NN vector_NN alone_RB (_( fluconazole_NP MIC_NP ,_, 0.5_CD mug/ml_NN ;_: itraconazole_NP MIC_NP ,_, <0.03_NN mug/ml_NN )_) ,_, transformants_NNS harboring_VBG the_DT C._NP albicans_NP CDR2_NP gene_NN or_CC the_DT C._NP dubliniensis_NN CdCDR2_NP gene_NN were_VBD resistant_JJ to_TO fluconazole_VB (_( MIC_NP ,_, 32_CD to_TO 64_CD mug/ml_NN )_) and_CC itraconazole_NP (_( MIC_NP ,_, 0.5_CD to_TO 1_CD mug/ml_NN )_) ._SENT Analysis_NN of_IN CdCDR1_NP and_CC CdCDR2_NP mRNA_NP expression_NN levels_NNS in_IN C._NP dubliniensis_NN ._SENT |_SYM Total_NP RNA_NP was_VBD isolated_VBN from_IN C._NP dubliniensis_NN isolates_NNS and_CC in_IN vitro-generated_JJ derivatives_NNS with_IN reduced_VBN susceptibility_NN to_TO fluconazole_NN in_IN order_NN to_TO ascertain_VB the_DT expression_NN levels_NNS of_IN CdCDR1_NP and_CC CdCDR2_NP mRNA_NP in_IN these_DT organisms_NNS ._SENT As_IN reported_VBN by_IN Moran_NP et_FW al._FW ,_, all_DT clinical_JJ isolates_NNS and_CC in_IN vitro-generated_JJ derivatives_NNS of_IN C._NP dubliniensis_NN with_IN reduced_VBN susceptibility_NN to_TO fluconazole_NN displayed_VBD high_JJ levels_NNS of_IN CdMDR1_JJ mRNA_NN compared_VBN to_TO matched_VBN fluconazole-susceptible_JJ isolates_NNS ._SENT CdMDR1_JJ hybridization_NN signals_NNS in_IN the_DT resistant_JJ organisms_NNS CM2_NP ,_, CD57R_NP ,_, and_CC CD51-II_NP were_VBD 50-_CD to_TO 100-fold_NN higher_JJR than_IN those_DT observed_VBN in_IN matched_VBN fluconazole-susceptible_JJ isolates_NNS ._SENT Hybridization_NN of_IN these_DT RNAs_NP with_IN a_DT probe_NN specific_JJ for_IN the_DT CdCDR1_JJ gene_NN (_( homologous_JJ to_TO the_DT region_NN from_IN +1_NN to_TO +421_JJ of_IN the_DT CdCDR1_NP ORF_NP )_) revealed_VBD that_IN several_JJ of_IN these_DT isolates_NNS and_CC derivatives_NNS with_IN reduced_VBN susceptibility_NN to_TO fluconazole_NN also_RB displayed_VBD comparatively_RB minor_JJ increases_NNS in_IN levels_NNS of_IN CdCDR1_JJ mRNA_NN expression_NN relative_JJ to_TO matched_VBN fluconazole-susceptible_JJ isolates_NNS ._SENT The_DT oral_JJ clinical_JJ isolate_NN CM2_NP (_( fluconazole_NP MIC_NP ,_, 32_CD mug/ml_NN )_) displayed_VBD a_DT twofold-higher_NN level_NN of_IN CdCDR1_JJ mRNA_NN compared_VBN to_TO the_DT matched_VBN fluconazole-susceptible_JJ isolate_NN CM1_NP (_( fluconazole_NP MIC_NP ,_, 0.5_CD mug/ml_NN )_) recovered_VBD from_IN the_DT same_JJ patient_NN ._SENT Isolates_VBZ CM1_NP and_CC CM2_NP both_CC express_VB the_DT full-length_JJ CdCdr1p_NP ._SENT Also_RB ,_, the_DT in_IN vitro-generated_JJ derivative_JJ CD57R_NP (_( fluconazole_NP MIC_NP ,_, 32_CD mug/ml_NN )_) ,_, which_WDT also_RB expresses_VBZ the_DT full-length_JJ CdCdr1p_NP ,_, displayed_VBD a_DT ninefold-higher_NN level_NN of_IN CdCDR1_JJ mRNA_NN than_IN the_DT fluconazole-susceptible_JJ parental_JJ isolate_NN CD57_JJ ._SENT Interestingly_RB ,_, the_DT oral_JJ clinical_JJ isolate_NN CD47-IIb_NP (_( fluconazole_NP MIC_NP ,_, 16_CD mug/ml_NN )_) ,_, which_WDT was_VBD found_VBN to_TO express_VB the_DT nonfunctional_JJ truncated_JJ CdCdr1p_NP ,_, expressed_VBD a_DT twofold-higher_NN level_NN of_IN CdCDR1_JJ mRNA_NN than_IN the_DT matched_VBN clinical_JJ isolate_NN CD47-I_NP (_( fluconazole_NP MIC_NP ,_, 8_CD mug/ml_NN )_) ._SENT However_RB ,_, in_IN vitro-generated_JJ derivatives_NNS of_IN the_DT fluconazole-susceptible_JJ C._NP dubliniensis_NN isolates_VBZ CD51-II_NP and_CC CD36_NP (_( fluconazole_NP MIC_NP ,_, 0.25_CD mug/ml_NN )_) ,_, which_WDT displayed_VBD reduced_VBN susceptibility_NN to_TO fluconazole_VB (_( fluconazole_NN MICs_NN were_VBD 32_CD to_TO 64_CD mug/ml_NN for_IN CD51-IIR_NP ,_, CD36R1_NP ,_, and_CC CD36R2_NP )_) ,_, displayed_VBD levels_NNS of_IN CdCDR1_JJ mRNA_NN that_WDT were_VBD similar_JJ to_TO or_CC reduced_VBN in_IN comparison_NN to_TO their_PP$ respective_JJ fluconazole-susceptible_JJ parental_JJ isolates_NNS ._SENT Both_DT CD36_NP and_CC CD51-II_NP were_VBD shown_VBN to_TO express_VB the_DT truncated_JJ 85-kDa_NP CdCdr1p_NP ._SENT Total_NP RNA_NP from_IN these_DT isolates_NNS and_CC derivatives_NNS was_VBD also_RB hybridized_VBN with_IN sequences_NNS specific_JJ for_IN CdCDR2_NP (_( homologous_JJ to_TO the_DT region_NN from_IN +1_NN to_TO +418_NN of_IN the_DT CdCDR2_NP ORF_NP )_) ._SENT However_RB ,_, expression_NN of_IN CdCDR2_NP mRNA_NP was_VBD not_RB detected_VBN in_IN any_DT of_IN the_DT isolates_NNS or_CC derivatives_NNS tested_VBD ._SENT Targeted_JJ disruption_NN of_IN CdCDR1_NP ._SENT |_SYM In_IN order_NN to_TO ascertain_VB the_DT role_NN of_IN the_DT CdCDR1_JJ gene_NN in_IN determining_VBG susceptibility_NN to_TO azole_NN antifungal_NN drugs_NNS in_IN C._NP dubliniensis_NN ,_, we_PP disrupted_VBD both_DT copies_NNS of_IN the_DT CdCDR1_JJ gene_NN in_IN a_DT C._NP dubliniensis_NN strain_NN by_IN using_VBG the_DT MPAR-flipper_NP technique_NN described_VBD by_IN Wirsching_NP et_FW al._FW ._SENT These_DT experiments_NNS were_VBD carried_VBN out_RP in_IN an_DT in_IN vitro-generated_JJ derivative_NN of_IN the_DT clinical_JJ isolate_NN CD57_NP (_( fluconazole_NP MIC_NP ,_, 0.5_CD mug/ml_NN )_) ,_, termed_VBD CD57R_NP ,_, which_WDT exhibits_VBZ reduced_VBN susceptibility_NN to_TO fluconazole_VB (_( fluconazole_NP MIC_NP ,_, 32_CD mug/ml_NN )_) ._SENT CD57R_NP was_VBD originally_RB generated_VBN by_IN successive_JJ subculture_NN of_IN the_DT fluconazole-susceptible_JJ isolate_NN CD57_JJ on_IN fluconazole-containing_VBG agar_NN medium_NN ._SENT CD57R_NP expresses_VBZ the_DT full-length_JJ CdCdr1p_NN and_CC showed_VBD a_DT ninefold_JJ increase_NN in_IN CdCDR1_NP mRNA_NP expression_NN levels_NNS relative_JJ to_TO a_DT matched_VBN fluconazole-susceptible_JJ isolate_NN (_( CD57_JJ )_) and_CC also_RB exhibits_VBZ increased_VBN CdCdr1_NP 